Abstract

Personalised medicine promises better outcomes for patients as biomarkers can identify groups with better responses to drugs or other treatments but also raises some technical and ethical challenges. Illumina has over 60% world market share for personalised genome sequencing and the European Bioinformatics Institute has been leading European researchers in mapping the genome and sharing information. In this talk they will explore the implications of $500 personalised genome testing for implications for patients, healthcare providers and technologists.

Speakers will include:

David Bentley (Chief Scientist of Illumina) pictured David will be speaking about their push to take the cost of a personal genome down to $500 and the early applications of their service for patient care.

Paul Flicek (Head of Vertebrate Genomics, European Bioinformatics Institute) Paul will talk about the challenges of software and data handling for the very large volumes of sensitive data that will be produced as personalised genome sequencing becomes more widespread.

The Healthcare SIG aims to provide a platform where mainstream technology members of the Cambridge Network can interact with those companies focused more specifically on healthcare issues, for the benefit of both.

The venue for this meeting is Mills and Reeve’s office at 112 Hills Road and the evening will start with registration at 6pm.

All members of the University of Cambridge may attend free of charge, but we do like you to register, which you can do via our website at: http://www.cambridgenetwork.co.uk/events/article/default.aspx?objid=67434